Insider trade

Chair sold ~$325K of JNJ shares in the open market

Traded Feb 20, 2026 · Filed Feb 23, 2026

Johnson & JohnsonJNJ

~$325K
Reported value · 1,322 sh @ $245.66: 25K
Holds after · shares reported: +6.7%
stock since the trade · S&P 500 +10.8%, $242.49 → $258.66 on Oct 1

Why it stands out

Johnson & Johnson's WW Chair, MedTech sold $325K of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 20, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 23, 2026

Chair$100K–$500K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$324,763

Shares × reported transaction price

Timing vs results

30 days after results of Jan 21, 2026, 53 days before results of Apr 14, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $242.49 on Feb 20, 2026, within 2% of its 52-week high, after a 17% rise over the previous 30 trading days

52-week range $146.36 (May 14, 2025) to $246.91 (Feb 19, 2026), 96% of the way up, from 251 adjusted closes. 30 trading days earlier: $207.49 on Jan 7, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Prezcobix on Feb 27, 2026, 7 days after this trade.

New use approved (efficacy supplement). Active ingredient: Cobicistat, Darunavir Ethanolate. From openFDA. Dates only; no link between the two is implied